B
OverallB-
Balance SheetClorox(CLX) looks like a solid but not cheap consumer staples franchise that is still working through execution noise. The core bull case rests on three facts. First, the company rebuilt profitability sharply in fiscal 2025, with revenue of $7.10B, gross margin of 45.0%, operating margin of 16.6%, and net income of $810M versus just $280M in fiscal 2024. Second, the portfolio still has real brand power in categories where trust and shelf presence matter, led by Health and Wellness at $2.70B of fiscal 2025 revenue, or 38.2% of sales. Third, management has now completed the final phase of the U.S. ERP rollout and closed the GOJO acquisition on April 1, 2026, adding an $800M sales platform in health and hygiene with at least $50M of run-rate cost synergies targeted.
The bear case is not hard to find either. Q3 fiscal 2026 showed why the stock still trades with a leash on it. Net sales rose 2% to $1.99B and adjusted EPS rose 13% to $1.64, but Clorox cut FY2026 guidance to net sales down about 6%, organic sales down about 9%, gross margin down 250 to 300 bps, and adjusted EPS of $5.45 to $5.65. Management tied a large part of that pressure to retailer inventory drawdown after the ERP transition, which it quantified as about 7.5 points of FY2026 sales pressure and a $0.90 EPS headwind. That is a real drag, but it is also a reminder that this is a business where operational mistakes echo through the P&L for quarters.
For a balanced, moderate-risk investor, CLX fits best as a steady compounder-in-repair rather than a classic deep-value bargain or a high-growth re-rating story. The stock’s trailing P/E of 15.8x and forward P/E of 13.9x are reasonable for a branded staples name, but not low enough to ignore the debt load, weak equity base, and near-term sales reset. The right stance is constructive but selective: the franchise quality is real, the recovery path is visible, and the valuation is close to fair rather than obviously mispriced.
The Clorox Company(CLX) is a consumer staples company founded in 1913 and headquartered in Oakland, California. It sells household and professional products worldwide through mass retailers, grocery outlets, warehouse clubs, dollar stores, drug and pet stores, home hardware channels, distributors, and e-commerce. The company had 7,600 employees and operates across four reporting segments: Health and Wellness, Household, Lifestyle, and International.
The portfolio is broad but still coherent. Core brands include Clorox, Clorox2, Pine-Sol, Scentiva, Tilex, Formula 409, CloroxPro, Clorox Healthcare, Glad, Fresh Step, Scoop Away, Kingsford, Hidden Valley, Brita, and Burt’s Bees. This is not a conglomerate built from random shelf space. It is a collection of repeat-purchase categories where efficacy, habit, and retailer relationships matter. That matters because consumers can postpone a sofa, but they still need trash bags, litter, bleach, and salad dressing.
Scale is meaningful, though not limitless. Fiscal 2025 revenue was $7.10B, and market capitalization stands near $11.66B. Institutional ownership is high at 85.4%, which fits the profile of a mature staples name held by index funds and quality-focused managers. Vanguard held 15.68M shares and BlackRock held 10.38M shares in the latest ownership snapshot. Analyst sentiment is cautious, with a consensus rating of 3.05 and a target of $115.47, alongside a breakdown of 2 Buy, 13 Hold, and 3 Sell ratings.
Leadership is stable. Linda Rendle serves as CEO and Chairman, and Luc Bellet is CFO. In the February 2026 earnings call, Rendle framed the current period as a transition year shaped by macro pressure and ERP disruption, while also pointing to digital transformation, innovation, and the planned GOJO acquisition as the next leg of growth. That is corporate language, but the plain-English version is simpler: fix the plumbing, relaunch the brands, and use health and hygiene to widen the moat.
Health and Wellness is the largest segment and the clearest strategic center of gravity. In fiscal 2025 it generated $2.70B of revenue, up from $2.49B in fiscal 2024, lifting its share of company sales to 38.2% from 36.2%. The segment includes cleaning and disinfecting products under Clorox, Pine-Sol, Scentiva, Tilex, Formula 409, and professional brands such as CloroxPro and Clorox Healthcare. That mix gives Clorox exposure to both household demand and institutional hygiene spending.
Household remains the second-largest segment at $2.00B of fiscal 2025 revenue, or 28.3% of total sales, up slightly from $1.95B in fiscal 2024. This segment houses Glad, Fresh Step, Scoop Away, and Kingsford. It is also where the company faces some of its sharpest competitive pressure. Management repeatedly called out litter and Glad as categories with elevated promotion and tougher share dynamics. In other words, this is where brand strength meets the blunt instrument of price competition.
Lifestyle produced $1.30B in fiscal 2025 revenue, or 18.4% of total sales, versus $1.28B in fiscal 2024. This segment includes Hidden Valley, Brita, and Burt’s Bees. The growth profile here is steadier than spectacular, but the brands are useful because they diversify the portfolio beyond cleaning and household consumables. Management specifically highlighted pressure in food from GLP-1 headwinds and promotion, while also pointing to share gains in shelf-stable dressing through price-pack architecture.
International is the smallest segment at $1.07B in fiscal 2025 revenue, or 15.1% of total sales, down from $1.16B in fiscal 2024. That decline matters because international had been one of the company’s growth levers in its longer-term algorithm. Even so, management still described international and professional businesses as meaningful contributors with potential for outsized growth contribution. The segment gives Clorox geographic reach, but it also adds FX exposure and operational complexity.
The segment mix tells a useful story. Clorox is becoming more concentrated in Health and Wellness, which is positive because that category benefits from stronger brand trust and more defensible product efficacy. At the same time, Household still carries a large weight and remains exposed to private label and promotional intensity. That mix shift is one reason the GOJO deal matters: it pushes the portfolio further toward professional and hygiene categories where the economics can be sturdier.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
The flagship product family is still the Clorox cleaning franchise, and recent management commentary points to that business as the company’s biggest growth driver and biggest business. In Q3 fiscal 2026 prepared remarks, management said cleaning was seeing consistent consumer engagement and innovation-led strength. That matters because when a staples company says its biggest business is also its biggest growth driver, the engine is at least firing, even if not yet at full throttle.
The most important recent launch is Clorox PURE, introduced in January 2026. Management described it as a new cleaning platform built around proprietary technology that destroys allergens. In the February 2026 call, Linda Rendle said the product had strong retailer support, good early consumer reviews, and double the company’s typical launch-size investment behind marketing and demand creation. In Q3 prepared remarks, management added that early sales were ahead of expectations, with favorable shelf placement and broad distribution.
That quote matters because it gets to the heart of what makes a flagship product valuable in staples. It is not enough to be on shelf. The product has to solve a problem consumers recognize and retailers can merchandise. Allergy relief is a cleaner story than vague premiumization. It gives Clorox a way to defend price and expand use cases at the same time.
Beyond PURE, Scentiva remains a useful proof point that Clorox can still refresh mature categories. Management said Scentiva Cherry Blossom was the brand’s top-performing item in Q3 fiscal 2026 prepared remarks. That is not a company-making event, but it shows the portfolio can still generate incremental demand through fragrance, format, and occasion-based innovation rather than relying only on price.
Glad is another flagship franchise, though one under more pressure. Management highlighted a new LeakGuard technology in premium trash bags, with an absorbent bottom layer designed to prevent leaks after tears. That is classic Clorox product logic: take a routine category, fix a specific frustration, and try to earn a premium. The challenge is that trash bags are also a category where private label can look good enough on a tough budget. So the product innovation is real, but the competitive bar is lower than in disinfecting.
Clorox’s main competitive advantage is brand trust in everyday categories where performance matters. The 10-K states that brand names and trademarks are highly important to the business, and the company competes on product performance, brand reputation, image, and price. In bleach, disinfecting, and professional hygiene, that trust has real economic value. A consumer may experiment with a cheaper sponge. They are less casual about disinfecting products, water filtration, or products used around food and family health.
Innovation is the second leg of the moat. Management has been explicit that the back half of fiscal 2026 is loaded with launches across major brands. Clorox PURE, Glad LeakGuard, the litter relaunch, and Hidden Valley Original Ranch with Avocado Oil all fit a pattern: solve a specific consumer problem, widen price-pack architecture, and support the launch with heavier marketing. Rendle said many of these innovations had already begun shipping, with shelf resets occurring in Q3 or early Q4.
That spending matters because innovation without shelf support is just PowerPoint with better lighting. Clorox is putting real dollars behind launches at a time when it has rebuilt margin enough to fund them. Fiscal 2025 gross margin reached 45.0%, up from 42.6% in fiscal 2024 and 38.9% in fiscal 2023. That recovery gives management room to invest rather than simply defend.
The GOJO acquisition strengthens the moat in a more structural way. GOJO closed on April 1, 2026, brings about $800M in sales, and is expected to generate at least $50M in run-rate cost synergies. Management said it should be neutral to adjusted EBITDA and adjusted EPS in year one, then accretive in year two. More important than the accounting is the strategic fit: GOJO deepens Clorox’s position in health and hygiene, a category where brand trust and professional relationships tend to be more durable than in commoditized household consumables.
Operations have been the central issue for Clorox since the cyberattack in 2023 and the subsequent ERP transformation. The company went live with its new ERP in July, then phased manufacturing facilities through transitions in July, October, and January. In the February 2026 call, CFO Luc Bellet said higher-than-expected shipments ahead of consumption created about 1 point of favorability in Q2, tied mainly to the final ERP phase, and that this would reverse in Q3.
That is the good news. The less pleasant part is the bill. Q3 fiscal 2026 gross margin was 43.2%, down 140 bps year over year, with pressure mainly from 210 bps of higher manufacturing and logistics costs, partly offset by 170 bps of cost savings. Selling and administrative expense was 13.7% of net sales and included $17M of strategic investments tied to digital capabilities and GOJO integration. This is the sort of quarter where the income statement reads like a repair invoice.
Still, there are signs the operational drag is easing. Management said service levels have stabilized, complexity and costs are coming down, and the ERP foundation should unlock productivity in supply chain, working capital, and SG&A over time. Bellet also said digital transformation adjustments would largely end after Q3, with about $0.08 of adjustment remaining in that quarter. In other words, the heavy lifting is mostly done, and the next test is whether the promised productivity shows up in reported numbers rather than in conference-call architecture.
Supply chain remains a real sensitivity. The 10-K highlights exposure to raw materials, transportation, labor, environmental liabilities, and hazardous-substance handling at some international facilities. It also notes that environmental remediation liabilities stood at $27M as of June 30, 2025. Those are manageable in size, but they reinforce a simple point: a company that sells bleach, chemicals, and packaged household goods does not get to operate in a frictionless spreadsheet.
Clorox operates in large, mature categories with modest underlying growth. Third-party market data cited in the research context estimates the global household cleaners market at $170.47B in 2026, growing toward $213.76B by 2031, a 4.63% CAGR. That is healthy enough to support innovation and mix gains, but not the kind of market that rescues weak execution. In this industry, share gains matter more than category miracles.
Management’s own category view is more restrained in the near term. In the February 2026 call, Rendle said Clorox expected category growth of 0% to 1% in the back half of the year and described the consumer as focused on value, trading across pack sizes, increasing trips, and moving toward value-oriented channels. That is a classic staples environment: volumes do not collapse, but mix gets messy and pricing power becomes selective rather than broad.
Longer term, Clorox’s Ignite strategy assumes categories return to roughly 2% to 2.5% growth, with another point of growth from professional and international businesses. That framework matters because it shows what management thinks a normalized environment looks like. The gap between that algorithm and current guidance is the whole investment debate. If the current slump is mostly ERP distortion and temporary consumer pressure, earnings power can recover. If not, the stock deserves only a market-like multiple.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
Clorox’s customer base is broad, but its retail concentration is meaningful. Walmart accounted for 25% of consolidated net sales in fiscal 2024. That is a major advantage in distribution and a major risk in bargaining power. When one customer represents a quarter of sales, shelf access is a moat and a dependency at the same time. It is a bit like owning the best house on a street where one landlord controls the traffic.
End consumers skew toward routine household replenishment rather than discretionary spending. The company sells through grocery, mass retail, warehouse clubs, dollar stores, and e-commerce, which means it reaches value shoppers and convenience shoppers alike. Management said consumers are trading up to larger sizes, down to smaller sizes, and showing more stock-up behavior in categories where that is normal. That pattern supports demand resilience, but it also pressures price mix because shoppers are optimizing value more aggressively.
The professional customer set is increasingly important. CloroxPro, Clorox Healthcare, and now GOJO extend the company beyond household shelves into institutional hygiene. That matters because professional demand can be stickier, more specification-driven, and less exposed to private-label substitution than a consumer standing in front of a wall of trash bags comparing unit prices.
Competition is intense across nearly every Clorox category. The company’s filings explicitly cite competition from nationally advertised brands and private label. Relevant branded rivals include Procter & Gamble(PG), SC Johnson, Reckitt, Henkel, Unilever, and Church & Dwight(CHD), while retailer brands remain a constant pressure in bags, wraps, litter, and other value-sensitive categories.
The risk is not uniform across the portfolio. Cleaning and disinfecting are more defensible because efficacy and trust matter. Household products like trash bags and cat litter are more exposed to commoditization. Management repeatedly identified Glad and litter as pressure points, with elevated promotions and tougher competition. That lines up with the broader industry trend that private label is gaining credibility and shelf space. In categories where the consumer sees little difference, the brand owner has to prove it every week.
Clorox still has advantages. More than 80% of sales come from brands that are No. 1 or No. 2 in their categories, according to the broader business context. Retail relationships are deep, brand recognition is high, and the company has scale in merchandising and advertising. But the competitive picture is mixed rather than dominant. This is not a monopoly hiding in plain sight. It is a strong franchise that has to keep earning its shelf space the hard way.
The macro backdrop for Clorox is a tug-of-war between staples resilience and consumer value-seeking. Management described the consumer environment as challenging, with weaker confidence and continued focus on value. That shows up in channel shifts, pack-size changes, and more promotional intensity. For a staples company, this is survivable, but it compresses the room for error. Price increases become harder to hold, and volume recovery has to come from better execution and better products.
Input costs remain another swing factor. Clorox’s April 30, 2026 guidance update said gross margin headwinds include higher energy costs tied to the Middle East conflict. The 10-K also flags exposure to commodity prices, transportation, inflation, foreign exchange, and tariff impacts. These are not abstract risks. Q3 fiscal 2026 already showed how higher manufacturing and logistics costs can erase part of the benefit from cost savings.
Geopolitical and regulatory risk is also embedded in the business model. The company handles hazardous substances at some international facilities, faces environmental remediation obligations, and notes that a downgrade below investment grade could trigger collateral requirements under derivative agreements. None of this looks existential today, but it reinforces why staples investors should not confuse low beta with no risk. CLX’s beta is 0.645, which says the stock is calmer than the market. It does not say the business is simple.
Debt remains a concern alongside a weak equity base, even after the company rebuilt profitability in fiscal 2025.
Unlock the full analysis
Subscribers get the complete breakdown — grades, rationale, and specific targets.
Get Full AccessRevenue rose to $7.10B in fiscal 2025 and net income jumped to $810M, but FY2026 guidance points to a sharp sales and margin reset.
Unlock the full analysis
Subscribers get the complete breakdown — grades, rationale, and specific targets.
Get Full AccessManagement now sees FY2026 net sales down about 6% and adjusted EPS of $5.45 to $5.65 after ERP-related inventory drawdown pressure.
Unlock the full analysis
Subscribers get the complete breakdown — grades, rationale, and specific targets.
Get Full AccessTrailing P/E of 15.8x and forward P/E of 13.9x suggest a reasonable but not cheap staples valuation near fair value.
Unlock the full analysis
Subscribers get the complete breakdown — grades, rationale, and specific targets.
Get Full AccessThe stock sits between the $98 buy level and the $126 sell level, with $112 marking the fair value midpoint.
Unlock the full analysis
Subscribers get the complete breakdown — grades, rationale, and specific targets.
Get Full AccessClorox(CLX) remains a high-quality household and hygiene franchise with real brand equity, strong cash generation, and a credible path to steadier growth once ERP distortions fade. Fiscal 2025 proved the company can rebuild margins, and recent product launches show the innovation engine is still alive. The GOJO acquisition also makes strategic sense by pushing the portfolio further into health and hygiene, where Clorox’s strengths are more durable.
But quality alone is not a reason to overpay. Fiscal 2026 guidance is weak, leverage is meaningful, and some of the most important categories remain promotional and competitive. That leaves CLX in a middle ground that many staples investors know well: a good business, a decent stock, and a better buy on weakness than on enthusiasm. For now, the evidence supports patience over chase.
CLX is a Hold right now, not a clear Buy. The company has a strong brand portfolio and rebuilt profitability in fiscal 2025, but FY2026 guidance was cut sharply because ERP-related inventory drawdown is still pressuring sales and margins.
Clorox's fair value is $112. We arrive at that by weighing its trailing P/E of 15.8x and forward P/E of 13.9x against a branded staples profile that is recovering, but still facing a FY2026 sales reset, margin pressure, and a debt load that keeps the multiple from expanding.
Management cut FY2026 guidance to net sales down about 6%, organic sales down about 9%, gross margin down 250 to 300 bps, and adjusted EPS of $5.45 to $5.65. The main driver was retailer inventory drawdown after the ERP transition, which the company said would create about 7.5 points of sales pressure and a $0.90 EPS headwind.
Health and Wellness is the most important segment, with $2.70B of fiscal 2025 revenue, or 38.2% of sales. It is the clearest strategic center of gravity because it combines household cleaning with professional hygiene brands and is the area most likely to benefit from the GOJO acquisition.
A cleaner ERP recovery, better retailer inventory normalization, and contribution from the GOJO acquisition could all help. If Clorox can hold margins near the fiscal 2025 level and grow its health and hygiene mix, the stock has room to move toward the higher end of its valuation range.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access
The Clorox Company (CLX) drops sharply after cutting full-year profit guidance and warning that gross margins will weaken more than expected. The consumer staples name posted a mixed quarter, but investors are focusing on lower earnings power, margin pressure, and a tougher near-term outlook.
Energy earnings stole the spotlight as Valero, ConocoPhillips, and Exxon Mobil topped estimates, while Linde and Dominion Energy showed steady execution. But the market’s reaction was mixed, reminding investors that a strong quarter does not always translate into a strong stock move.
U.S. growth held up, but inflation stayed stubborn and layoffs remained scarce. Stronger-than-expected spending, a hot PCE reading, and a jump in ISM prices reinforced the Fed’s higher-for-longer stance, even as markets briefly rallied on softer GDP and earnings support.